SOKA, Japan–(BUSINESS WIRE)–Lightnix Inc. (2-3-9 Takasago, Soka-shi, Saitama Prefecture; CEO: Shosuke Kiba) has decided to participate as a partner company in “Innovation Infusion Japan� (“i2.JP”; Website: https://www.i2jp.net/en/index.html), an initiative sponsored by AstraZeneca K.K. (Kita-ku, Osaka-shi, Osaka Prefecture; President: Takafumi Horii).
i2.JP is a new initiative that promotes open innovations in the healthcare field. Its goal is to contribute to next-generation healthcare through partnerships with companies, academia, and government.
Lightnix seeks to create innovations in healthcare through the development of intradermal vaccine injection devices and other new drug delivery methods.
By leveraging its strengths in this field, the company aims to resolve healthcare issues related to vaccine and drug delivery in partnership with both the public and private sectors, including the healthcare sector and industries worldwide participating in i2.JP.
Contacts
Lightnix Inc.
Akihiro ISUMI, General Manager
+81-48-951-3637
info@lightnix.jp
https://www.lightnix.jp/en/
Highlights of FY23/24 Results For the financial year ended 31 March 2024, total sales amounted…
HONG KONG SAR - Media OutReach Newswire - 16 May 2024 - Primarily due to…
This United States Trade and Development Agency (USTDA)-funded technical assistance aims to improve public mobility…
TYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield®…
Charter increases CoolCo’s total revenue backlog to almost $1.9 billion LONDON--(BUSINESS WIRE)--Cool Company Ltd. (NYSE:…
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members…